UK Medical Device Testing Reaches Record High 2025
The United Kingdom is setting new benchmarks in medical device innovation. Clinical investigations of breakthrough medical devices reached their highest level ever recorded in 2025, signaling a dramatic shift in the country’s global standing as a hub for cutting-edge health technology. From AI-powered diagnostics to revolutionary brain stimulation devices, the UK is increasingly becoming the first destination for companies seeking to test next-generation medical technologies.
MHRA Reports 17% Rise in Clinical Investigations
New figures released by the Medicines and Healthcare products Regulatory Agency (MHRA) reveal a 17% rise in approved clinical investigations in 2025 compared with the previous year. This sharp increase reflects a growing preference among global medtech companies to choose Great Britain as the testing ground for their most advanced health technologies.
The MHRA, which is responsible for regulating all medicines and medical devices in the UK, has attributed this growth to its faster approval processes, stronger regulatory support, and a clear focus on patient safety alongside innovation. MHRA Chief Executive Lawrence Tallon described 2025 as “a standout year for medical device innovation in the UK,” adding that the country is now attracting some of the world’s most exciting technologies — particularly in the area of brain health.
Neurotechnology Leads the Surge
Studies in Neurology Double Since 2024
One of the most striking trends in this year’s data is the dramatic growth of neurotechnology research. Clinical investigations in this field have doubled since 2024 and now account for approximately one quarter of all UK applications. This surge is being driven by a global push to find better treatments for conditions such as dementia, Parkinson’s disease, and epilepsy — areas where existing therapies often fall short of providing adequate relief.
Landmark Approvals in Brain Stimulation Research
Among the most significant recent approvals is a feasibility study exploring whether deep brain stimulation can help treat disorders of addiction. Additionally, a pioneering first-in-human paediatric trial led by Great Ormond Street Hospital, University College London, and the University of Oxford is now testing a rechargeable brain stimulation device designed to reduce seizure frequency in children with severe, treatment-resistant epilepsy. These breakthroughs represent a new frontier in how the UK approaches neurological disease management.
The MHRA is also part of a UK-wide partnership led by Newcastle University to update national guidance on neurotechnology research, making it faster and clearer for clinicians, researchers, and companies to launch studies involving devices that interact with the brain and nervous system.
AI-Powered Medical Devices on the Rise
Intelligent Tools Transforming Diagnosis and Care
Artificial intelligence is reshaping the medical device landscape, and the UK is at the forefront of this transformation. AI-powered devices approved for clinical investigation in 2025 include tools that scan medical images to detect disease earlier, guide treatment decisions in real time, and personalise care pathways for individual patients.
H3: Digital Therapeutics Entering Real-World Studies
Among the newly approved studies is a digital therapeutic application designed for people living with chronic obstructive pulmonary disease (COPD). The app dynamically adjusts treatment recommendations in real time while simultaneously providing clinicians with richer data to personalise patient care. Studies in advanced eye technologies have also risen, as companies develop new methods to protect vision and restore sight in patients with degenerative conditions.
Faster Approvals and Stronger Regulatory Support
Speed and reliability are central to the UK’s appeal as a medtech testing destination. The MHRA has met 100% of its statutory deadlines for clinical investigation applications since September 2023. In 2025, average approval times stood at just 51 days — nine days faster than the 60-day statutory target. This level of efficiency gives companies the certainty they need to commit resources and plan their research timelines.
Mark Grumbridge, Head of Clinical Investigations at the MHRA, noted that the agency has expanded specialist advice meetings for complex technologies including neurotechnology, cardiac devices, surgical robotics, and artificial intelligence. Researchers also receive hands-on scientific support to help design safer, more robust studies.
New Measures to Back Innovation and Small Companies
Fee Waivers for Micro and Small UK Firms
Recognising that early-stage financial barriers can prevent promising technologies from advancing, the MHRA introduced a pilot fee waiver scheme from January 2026. Under this programme, micro and small UK firms are exempt from fees for clinical investigation applications, helping unlock high-potential innovations that might otherwise stall due to cost constraints.
Early Market Access and Enhanced Support
In addition to fee waivers, the MHRA has introduced early market access pathways for promising devices and enhanced support structures for high-impact technologies. These measures collectively aim to reduce unnecessary bureaucratic barriers while maintaining rigorous safety standards that protect both patients and the integrity of clinical research.
What This Means for NHS Patients
For patients across the UK, the record growth in clinical investigations translates into earlier access to potentially life-changing technologies. For the NHS, it means better tools to diagnose disease, manage long-term illness, and deliver more precise treatment — at a time when healthcare systems are under significant pressure to improve outcomes while managing costs.
The Association of British HealthTech Industries (ABHI) welcomed the MHRA’s focus, noting that the UK’s ability to attract clinical investigations is a key signal of its competitiveness for HealthTech investment. A transparent and internationally aligned regulatory system enables companies to generate evidence, scale new technologies, and deliver patient benefits more quickly.
UK Cementing Its Global Medtech Leadership
Together, the record growth in clinical investigations and the MHRA’s comprehensive innovation drive aim to cement the UK’s position as a global leader in medical technology. With neurotechnology studies doubling, AI-enabled devices expanding rapidly, and regulatory approval times beating statutory targets, the UK is demonstrating that it can offer the speed, certainty, and expertise that global medtech companies demand. The next generation of life-changing medical devices may well be pioneered right here.
